GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Cefiderocol (Fetroja)

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug6 sources available - open source summaries, references and comparisons

Fetroja

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (2)
Review first - source-specific qualification

The recovered institutional page has different printed boundaries

The official label uses CrCl >=120; UCSF prints >120 beside 60-119. The upper effluent band is >=4.1 L/hour in the label versus >4 in UCSF.

Before applying: For exactly CrCl 120 the official label is explicit. Preserve the institutional discrepancy and seek clarification for effluent values between printed bands; do not interpolate. This is a wording/boundary comparison, not evidence of different clinical outcomes.

Evidence for this qualification

Selected-source qualification; independent clinician review pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (6)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
CRRT effluent guidance is not an intermittent-HD dose table

The selected official and mirror tables agree. Their CRRT guidance is explicitly initial and depends on effluent rather than a CrCl band.

Before applying: Confirm modality and L/hour effluent, then reassess residual function and clinical status; do not interpolate a new algorithm.

Also check: CRRT effluent guidance is not an intermittent-HD dose table

Official source

Cefiderocol - FETROJA adult intravenous therapy

Product / population
Adult cefiderocol IV; distinguish non-dialysis CrCl from intermittent HD and CRRT effluent. Institutional protocols remain separately attributed.
Renal measure
Cockcroft-Gault CrCl mL/min; CRRT effluent L/hour
Before using this finding

At exactly CrCl 120, use the explicit label boundary rather than filling a gap by assumption.

Retain published CRRT precision and seek specialist clarification for values between bands.

Selected named sections only; not a complete monograph or independent clinical approval.

Exact DailyMed HTML identity and selected sections read. Raw SPL XML, original-source hashes and complete revision history were not retrieved. Label retrieval does not establish current availability.

Renal dosing, restrictions and evidence limits

For Cockcroft-Gault CrCl >=120 mL/min, the label specifies 2 g every 6 hours over 3 hours; 60-119 uses 2 g every 8 hours. Below 60: 30-59 uses 1.5 g every 8 hours, 15-29 uses 1 g every 8 hours, and <15 (with or without intermittent HD) uses 0.75 g every 12 hours; all infuse over 3 hours. On HD days administer immediately after dialysis.

CRRT initial doses by effluent L/hour are: <=2, 1.5 g every 12 hours; 2.1-3, 2 g every 12 hours; 3.1-4, 1.5 g every 8 hours; >=4.1, 2 g every 8 hours. Reassess residual renal function and clinical status. These printed intervals are not interpolated.

The official CrCl threshold includes exactly 120; the retrieved UCSF heading does not.

Source revision: 3/2026 (highlights); DailyMed updated 2026-02-24 | Retrieved: 2026-09-10. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75c0c785-38e0-4049-a6fb-b77581f5b35c

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

FETROJA - cefiderocol intravenous injection

Authored v5.8; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

CRRT effluent-based initial regimen

Read the source and its limits

Cefiderocol - FETROJA adult intravenous therapy

Authored v5.9; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

CRRT effluent-based initial regimen

Read the source and its limits

GlobalRPh RX List - FETROJA

Authored v5.8; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

CRRT effluent-based initial regimen

Read the source and its limits

UCSF cefiderocol - fresh institutional follow-up

Authored v5.9; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

CRRT effluent-based initial regimen

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 2 source difference / applicability notes

Official product label

FETROJA - adult renal and CRRT dosing

Adults; exact named U.S. product. Selected dose/renal summary, not the full prescribing information.

Renal method: Cockcroft-Gault CrCl; CRRT effluent flow in L/hour.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Official product label

FETROJA - cefiderocol intravenous injection

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Dialysis evidence: CRRT effluent-based initial regimen

FETROJA intravenous cefiderocol in adults; renal function, intermittent HD and CRRT effluent are separate dosing contexts.

Renal method: Cockcroft-Gault CrCl in mL/min; CRRT effluent in L/hour
Retrieved: 2026-09-10

Read local renal resultOpen original reference
Official product label

Cefiderocol - FETROJA adult intravenous therapy

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

At exactly CrCl 120, use the explicit label boundary rather than filling a gap by assumption.

Retain published CRRT precision and seek specialist clarification for values between bands.

Dialysis evidence: CRRT effluent-based initial regimen

Adult cefiderocol IV; distinguish non-dialysis CrCl from intermittent HD and CRRT effluent. Institutional protocols remain separately attributed.

Renal method: Cockcroft-Gault CrCl mL/min; CRRT effluent L/hour
Retrieved: 2026-09-10

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - FETROJA

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Dialysis evidence: CRRT effluent-based initial regimen

FETROJA intravenous cefiderocol in adults; renal function, intermittent HD and CRRT effluent are separate dosing contexts.

Renal method: Cockcroft-Gault CrCl in mL/min; CRRT effluent in L/hour
Retrieved: 2026-09-10

Read local renal resultOpen original reference
Professional guidance

UCSF - cefiderocol and effluent-specific continuous therapy

Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Professional guidance

UCSF cefiderocol - fresh institutional follow-up

Professional guidance with defined scope. Publication date, institutional setting and source limitations remain controlling. This is not automatic preference over another source.
Before using this finding

Retrieval failure resolved; the numeric-boundary discrepancy remains open.

Institutional >120 is not identical to the label >=120.

Dialysis evidence: CRRT effluent-based initial regimen

Adult cefiderocol IV; distinguish non-dialysis CrCl from intermittent HD and CRRT effluent. Institutional protocols remain separately attributed.

Renal method: CrCl mL/min (equation not specified on this page); continuous-dialysis effluent L/hour
Retrieved: 2026-09-10

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

CRRT effluent guidance is not an intermittent-HD dose tableThe recovered institutional page has different printed boundaries

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 2 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

selected concordance and crrt scope

CRRT effluent guidance is not an intermittent-HD dose table

The selected official and mirror tables agree. Their CRRT guidance is explicitly initial and depends on effluent rather than a CrCl band.

How to use this: Confirm modality and L/hour effluent, then reassess residual function and clinical status; do not interpolate a new algorithm.

GlobalRPh RX List - FETROJAFETROJA - cefiderocol intravenous injection

Source-specific interpretation; independent clinician adjudication pending.

numeric boundary disagreement

The recovered institutional page has different printed boundaries

The official label uses CrCl >=120; UCSF prints >120 beside 60-119. The upper effluent band is >=4.1 L/hour in the label versus >4 in UCSF.

How to use this: For exactly CrCl 120 the official label is explicit. Preserve the institutional discrepancy and seek clarification for effluent values between printed bands; do not interpolate. This is a wording/boundary comparison, not evidence of different clinical outcomes.

Cefiderocol - FETROJA adult intravenous therapyUCSF cefiderocol - fresh institutional follow-up

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeFETROJA - adult renal and CRRT dosingFETROJA - cefiderocol intravenous injectionCefiderocol - FETROJA adult intravenous therapyGlobalRPh RX List - FETROJAUCSF - cefiderocol and effluent-specific continuous therapyUCSF cefiderocol - fresh institutional follow-up
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75c0c785-38e0-4049-a6fb-b77581f5b35c

Product and population scope

Adult Cefiderocol (Fetroja). Use only the product, route, indication and renal-replacement setting explicitly stated in the source protocol selected below. Sources are alternatives to compare, not ingredients of a blended regimen.

SCOPE-cefiderocol · Source section: Editorial scope; each clinical recommendation is separately attributed belowRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

FETROJA - adult renal and CRRT dosing

Open original reference

Open / share this exact local source

NIH/NLM DailyMed - U.S. product labeling · Adults; exact named U.S. product. Selected dose/renal summary, not the full prescribing information.

Renal method: Cockcroft-Gault CrCl; CRRT effluent flow in L/hour.
Source date: DailyMed updated 2026-02-24.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Infuse every dose IV over 3 hours for labeled adult cUTI/pyelonephritis or HABP/VABP.

Cockcroft-Gault CrCl (mL/min)DoseInterval
>=1202 gEvery 6 hours
60-1192 gEvery 8 hours
30-591.5 gEvery 8 hours
15-291 gEvery 8 hours
<15, with or without IHD750 mgEvery 12 hours

Start IHD-day dosing immediately after dialysis. CRRT initial doses depend on effluent: <=2 L/hour, 1.5 g every 12 hours; 2.1-3, 2 g every 12 hours; 3.1-4, 1.5 g every 8 hours; >=4.1, 2 g every 8 hours. Clarify values between the printed decimal ranges. Reassess residual kidney function and clinical response. The label warns of increased mortality observed in a carbapenem-resistant infection trial.

RDM30-071-cefiderocol-1 · Source locator: FETROJA - adult renal and CRRT dosing; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75c0c785-38e0-4049-a6fb-b77581f5b35c
Retrieved
2026-09-05
DailyMed Set ID
75c0c785-38e0-4049-a6fb-b77581f5b35c
Renal-function method
Cockcroft-Gault CrCl; CRRT effluent flow in L/hour.
Source date/version
DailyMed updated 2026-02-24.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
e634ca268ab4b91d7c6ade94ec4821b7ccb7584950cd540f728661a0528a9fd4
Official

FETROJA - cefiderocol intravenous injection

Open original reference

Open / share this exact local source

DailyMed / Shionogi Inc. · FETROJA intravenous cefiderocol in adults; renal function, intermittent HD and CRRT effluent are separate dosing contexts.

Renal method: Cockcroft-Gault CrCl in mL/min; CRRT effluent in L/hour
Source date: 3/2026 (printed highlights); DailyMed updated 2026-02-24
Retrieved: 2026-09-10

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Dialysis evidence: CRRT effluent-based initial regimen

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Using Cockcroft-Gault CrCl (mL/min), the adult regimen is 2 g every 8 hours at 60-119; 1.5 g every 8 hours at 30-59; 1 g every 8 hours at 15-29; and 0.75 g every 12 hours below 15 with or without intermittent HD. At >=120 use 2 g every 6 hours. Infuse over 3 hours and administer immediately after intermittent HD.

Initial CRRT doses by effluent L/hour: <=2, 1.5 g every 12 hours; 2.1-3, 2 g every 12 hours; 3.1-4, 1.5 g every 8 hours; >=4.1, 2 g every 8 hours. Tailor for residual renal function and clinical status. These printed intervals are retained, not interpolated into an automated algorithm.

RDM58-official-cefiderocol-4cceb3a62f-C1 · Source locator: Sections 2.1-2.2 Tables 1-2, 8.6; printed date fields

Source-specific limits

Selected sections only; not a complete prescribing monograph or independent clinician approval.

Exact DailyMed HTML identity and named sections read. Raw SPL XML, original document hash and complete revision history were not obtained. Availability is not established by label retrieval.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75c0c785-38e0-4049-a6fb-b77581f5b35c
Retrieved
2026-09-10
Exact label title
FETROJA - cefiderocol intravenous injection
DailyMed Set ID
75c0c785-38e0-4049-a6fb-b77581f5b35c
Labeler
Shionogi Inc.
DailyMed page updated
2026-02-24
Label revision
3/2026 (printed highlights); DailyMed updated 2026-02-24
Renal-function method
Cockcroft-Gault CrCl in mL/min; CRRT effluent in L/hour
Source date/version
3/2026 (printed highlights); DailyMed updated 2026-02-24
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
b12c17a9aa03ed5a226020c30231f4d4876071fa3257619be37a2d96d1ad3191
Official

Cefiderocol - FETROJA adult intravenous therapy

Open original reference

Open / share this exact local source

DailyMed / Shionogi Inc. · Adult cefiderocol IV; distinguish non-dialysis CrCl from intermittent HD and CRRT effluent. Institutional protocols remain separately attributed.

Renal method: Cockcroft-Gault CrCl mL/min; CRRT effluent L/hour
Source date: 3/2026 (highlights); DailyMed updated 2026-02-24
Retrieved: 2026-09-10

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

At exactly CrCl 120, use the explicit label boundary rather than filling a gap by assumption.

Retain published CRRT precision and seek specialist clarification for values between bands.

Dialysis evidence: CRRT effluent-based initial regimen

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

For Cockcroft-Gault CrCl >=120 mL/min, the label specifies 2 g every 6 hours over 3 hours; 60-119 uses 2 g every 8 hours. Below 60: 30-59 uses 1.5 g every 8 hours, 15-29 uses 1 g every 8 hours, and <15 (with or without intermittent HD) uses 0.75 g every 12 hours; all infuse over 3 hours. On HD days administer immediately after dialysis.

CRRT initial doses by effluent L/hour are: <=2, 1.5 g every 12 hours; 2.1-3, 2 g every 12 hours; 3.1-4, 1.5 g every 8 hours; >=4.1, 2 g every 8 hours. Reassess residual renal function and clinical status. These printed intervals are not interpolated.

The official CrCl threshold includes exactly 120; the retrieved UCSF heading does not.

RDM59-official-cefiderocol-4cceb3a62f-C1 · Source locator: Sections 2.1 and 2.2, Tables 1 and 2

Source-specific limits

Selected named sections only; not a complete monograph or independent clinical approval.

Exact DailyMed HTML identity and selected sections read. Raw SPL XML, original-source hashes and complete revision history were not retrieved. Label retrieval does not establish current availability.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75c0c785-38e0-4049-a6fb-b77581f5b35c
Retrieved
2026-09-10
Exact label title
Cefiderocol - FETROJA adult intravenous therapy
DailyMed Set ID
75c0c785-38e0-4049-a6fb-b77581f5b35c
Labeler
Shionogi Inc.
DailyMed page updated
2026-02-24
Label revision
3/2026 (highlights); DailyMed updated 2026-02-24
Renal-function method
Cockcroft-Gault CrCl mL/min; CRRT effluent L/hour
Source date/version
3/2026 (highlights); DailyMed updated 2026-02-24
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
40aa6c76f01ea47a1a8c3f3088269100adf285770dc74a709767190ca9557971
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - FETROJA

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · FETROJA intravenous cefiderocol in adults; renal function, intermittent HD and CRRT effluent are separate dosing contexts.

Renal method: Cockcroft-Gault CrCl in mL/min; CRRT effluent in L/hour
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-10

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Dialysis evidence: CRRT effluent-based initial regimen

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The retrieved mirror retains Cockcroft-Gault CrCl bands and separate CRRT effluent-flow recommendations. Its selected renal/CRRT tables agree with the separately retrieved official sections in this pass.

CRRT amounts are initial guidance, with residual kidney function and clinical status requiring reassessment. Retain effluent units in L/hour; do not substitute a weight-normalized effluent number or apply the intermittent-HD schedule to continuous therapy. The statement of selected-section agreement does not approve the full monograph.

RDM58-rxlist-cefiderocol-adc723a14a-C1 · Source locator: Dosage: renal adjustment Tables 1-2; Use in Specific Populations: Renal Impairment

Source-specific limits

Selected sections only; not a complete prescribing monograph or independent clinician approval.

A hosted label mirror is not independent corroboration of its underlying label. Official confirmation remains pending unless a separate official card is shown.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/fetroja-drug/
Retrieved
2026-09-10
Renal-function method
Cockcroft-Gault CrCl in mL/min; CRRT effluent in L/hour
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
9d4101a01526242c8da197ad7cf2928cad76591b1f06e5e8620d1d821d6eafff
Separate professional-source layer

University and professional protocols

Professional

UCSF - cefiderocol and effluent-specific continuous therapy

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

All doses are IV over 3 hours. CrCl >120 mL/min: 2 g every 6 hours; 60-119: 2 g every 8 hours; 30-59: 1.5 g every 8 hours; 15-29: 1 g every 8 hours; <15: 750 mg every 12 hours. The source omits exactly 120.

Intermittent HD: 750 mg every 12 hours. Continuous-therapy effluent <=2 L/hour: 1.5 g every 12 hours; 2.1-3: 2 g every 12 hours; 3.1-4: 1.5 g every 8 hours; >4: 2 g every 8 hours. Intermediate decimal flow values not assigned by these printed ranges need clarification. These flow-specific regimens supersede a generic low-CrCl row for the relevant modality.

RDM30-040-cefiderocol-1 · Source locator: UCSF - cefiderocol and effluent-specific continuous therapy; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/cefiderocol
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
e2b65d51046c014daafb528d446162e63e3cfad8e04dc0d588e9312425bf6b14
Professional

UCSF cefiderocol - fresh institutional follow-up

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adult cefiderocol IV; distinguish non-dialysis CrCl from intermittent HD and CRRT effluent. Institutional protocols remain separately attributed.

Renal method: CrCl mL/min (equation not specified on this page); continuous-dialysis effluent L/hour
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-10

Professional guidance with defined scope. Publication date, institutional setting and source limitations remain controlling. This is not automatic preference over another source.
Before using this finding

Retrieval failure resolved; the numeric-boundary discrepancy remains open.

Institutional >120 is not identical to the label >=120.

Dialysis evidence: CRRT effluent-based initial regimen

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The institutional table lists 2 g every 6 hours for CrCl >120 mL/min and 2 g every 8 hours for 60-119. Its other non-dialysis doses and intermittent-HD 750 mg every 12 hours align with the selected official table; infusions run over 3 hours.

Its continuous-dialysis bands use effluent <=2, 2.1-3, 3.1-4 and >4 L/hour, paired respectively with 1.5 g every 12 hours, 2 g every 12 hours, 1.5 g every 8 hours and 2 g every 8 hours. Use is restricted to Infectious Diseases or Antimicrobial Stewardship.

Exactly CrCl 120 is omitted by the printed >120 and 60-119 headings. The upper effluent boundary is >4 rather than the label's >=4.1. Preserve both differences; do not imply a new interpolation rule.

RDM59-professional-cefiderocol-4079b6c5d9-C1 · Source locator: Adult non-dialysis and intermittent/continuous-HD tables; restriction note

Source-specific limits

Selected named sections only; not a complete monograph or independent clinical approval.

Institutional guidance, not a universal protocol; local specialist and patient-context review remain necessary.

Source identity and provenance
Source family
professional_guidance
Source
https://idmp.ucsf.edu/content/cefiderocol
Retrieved
2026-09-10
Renal-function method
CrCl mL/min (equation not specified on this page); continuous-dialysis effluent L/hour
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
4a4744185f537fb3c733fe6a0e0a9c58a2b4c3f4bf096fffdd83a4e48d1db929

Provenance and preservation

Additional summaries stored on this page: 3 official-label, 1 RX List, 2 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75c0c785-38e0-4049-a6fb-b77581f5b35c
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
40669e68b7cebc058371d298a8f252b8ef1767506a2860fbd4cf6847655ab32d
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report